JP2012176990A5 - - Google Patents

Download PDF

Info

Publication number
JP2012176990A5
JP2012176990A5 JP2012137900A JP2012137900A JP2012176990A5 JP 2012176990 A5 JP2012176990 A5 JP 2012176990A5 JP 2012137900 A JP2012137900 A JP 2012137900A JP 2012137900 A JP2012137900 A JP 2012137900A JP 2012176990 A5 JP2012176990 A5 JP 2012176990A5
Authority
JP
Japan
Prior art keywords
calcium salt
formulation
used according
active ingredient
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012137900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012176990A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012176990A publication Critical patent/JP2012176990A/ja
Publication of JP2012176990A5 publication Critical patent/JP2012176990A5/ja
Pending legal-status Critical Current

Links

JP2012137900A 2005-05-18 2012-06-19 粘膜内壁の生物物理学的な性質を変化させる製剤 Pending JP2012176990A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68235605P 2005-05-18 2005-05-18
US60/682,356 2005-05-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008512543A Division JP2008540680A (ja) 2005-05-18 2006-05-18 粘膜内壁の生物物理学的な性質を変化させる製剤

Publications (2)

Publication Number Publication Date
JP2012176990A JP2012176990A (ja) 2012-09-13
JP2012176990A5 true JP2012176990A5 (OSRAM) 2012-10-25

Family

ID=37401509

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008512543A Pending JP2008540680A (ja) 2005-05-18 2006-05-18 粘膜内壁の生物物理学的な性質を変化させる製剤
JP2012137900A Pending JP2012176990A (ja) 2005-05-18 2012-06-19 粘膜内壁の生物物理学的な性質を変化させる製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008512543A Pending JP2008540680A (ja) 2005-05-18 2006-05-18 粘膜内壁の生物物理学的な性質を変化させる製剤

Country Status (13)

Country Link
US (2) US20070053844A1 (OSRAM)
EP (3) EP2402001A1 (OSRAM)
JP (2) JP2008540680A (OSRAM)
KR (1) KR20080018872A (OSRAM)
CN (2) CN102327285A (OSRAM)
AU (1) AU2006247077A1 (OSRAM)
BR (1) BRPI0609924A2 (OSRAM)
CA (1) CA2608752A1 (OSRAM)
EA (1) EA016072B1 (OSRAM)
IL (1) IL187427A0 (OSRAM)
NO (1) NO20076086L (OSRAM)
NZ (2) NZ593475A (OSRAM)
WO (1) WO2006125153A2 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
WO2010111640A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Anti-influenza formulations and methods
ATE538774T1 (de) * 2009-03-26 2012-01-15 Pulmatrix Inc Pharmazeutische formulierungen und verfahren zur behandlung von atemwegsinfektionen
WO2010111641A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
CA2754684A1 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
EP2410981B2 (en) 2009-03-26 2020-02-26 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
CN107096014B (zh) 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
CA2812417C (en) 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
WO2013052844A1 (en) 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
US9987235B2 (en) 2013-08-01 2018-06-05 Nicholas L. Abbott Methods and compositions for modifying mucous membranes
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
EP3858440A3 (en) * 2015-11-18 2021-11-03 The Board of Trustees of the Leland Stanford Junior University B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components
EP3737364A1 (en) * 2018-01-11 2020-11-18 Emphysema Solutions BV Compositions and methods for the treatment of lung emphysema and other forms of copd
US12337064B2 (en) 2018-09-05 2025-06-24 Sensory Cloud, Inc. Formulations and compositions for ortho- and/or retro-nasal delivery and associated systems, methods and articles
US12128067B2 (en) 2018-11-29 2024-10-29 Yildiz Teknik Universitesi Nasal solution with closed basin natural spring water characteristic and method for obtaining said nasal solution
US20220000767A1 (en) * 2020-07-06 2022-01-06 Sensory Cloud, Inc. Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi
US20230218661A1 (en) * 2022-01-10 2023-07-13 Sensory Cloud, Inc. Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx
US20220051592A1 (en) * 2020-08-17 2022-02-17 Massachusetts Institute Of Technology Respiratory system simulator systems and methods

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3229179C2 (de) * 1982-08-05 1986-04-17 A. Nattermann & Cie GmbH, 5000 Köln Lungensurfactant
US4637815A (en) * 1985-08-06 1987-01-20 Lemole Gerald M Irrigational hemostatic solution
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5175152A (en) * 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5571535A (en) * 1990-11-30 1996-11-05 Flowers; Marianne Treatment of topical infections
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
US5898037A (en) * 1992-11-13 1999-04-27 Marx; Alvin J. Formulations of magnesium compounds for local application and methods of treatment using the same
US5709202A (en) * 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
AUPM411494A0 (en) * 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5633003A (en) * 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
ATE218132T1 (de) * 1994-10-14 2002-06-15 Yamanouchi Pharma Co Ltd Azol-derivate
AU3705695A (en) * 1994-10-26 1996-05-23 Wellcome Foundation Limited, The Pharmaceutical composition comprising atovaquone
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en) * 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
EP1067839A1 (en) * 1998-04-08 2001-01-17 Eli Lilly And Company Pulmonary and nasal delivery of raloxifene
US5883084A (en) * 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
FR2780285B1 (fr) * 1998-06-29 2001-10-05 Goemar Lab Sa Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions
US6333051B1 (en) * 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
AU4979700A (en) * 1999-05-03 2000-11-17 Battelle Memorial Institute Compositions for aerosolization and inhalation
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
AU772096B2 (en) * 2000-03-14 2004-04-08 Sumika Enviro-Science Co., Ltd. Method for denaturing allergens
JP3481205B2 (ja) * 2000-11-24 2003-12-22 松下電器産業株式会社 インバータ制御用半導体装置および制御方法
AU2002245181B2 (en) * 2000-12-21 2006-06-29 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030232019A1 (en) * 2002-02-22 2003-12-18 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
CA2483917C (en) * 2002-05-02 2013-07-30 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
EP1503744A1 (en) * 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
WO2003103632A1 (en) * 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
US7534781B2 (en) * 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
WO2005004852A1 (en) * 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
GB0324897D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
SE528121C2 (sv) * 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
US20070275091A1 (en) * 2004-03-30 2007-11-29 Malcolm King Compositions And Methods For Improved Mucus Function
CA2574958A1 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US20070202051A1 (en) * 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
GB0818476D0 (en) * 2008-10-09 2008-11-12 Vectura Delivery Device Ltd Inhaler
WO2010111640A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Anti-influenza formulations and methods

Similar Documents

Publication Publication Date Title
JP2012176990A5 (OSRAM)
Pham et al. Strategies for the design of orally bioavailable antileishmanial treatments
TWI401079B (zh) 治療病毒感染之材料及方法
JP2013126989A5 (OSRAM)
JP2015509788A5 (OSRAM)
RU2017144619A (ru) Катионы одновалентных металлов сухих порошков для ингаляций
MX2009011218A (es) Microparticulas de acido nucleico para administracion pulmonar.
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
EP3988102B1 (en) Medicament for prevention or treatment of rhinovirus infection
WO2005084638A3 (en) Formulations decreasing infectivity of pulmonary diseases
PT2249866E (pt) Uso de um sal de ácido acetilsalicílico para o tratamento de infecções virais
NZ602441A (en) A fast dissolving pharmaceutical composition
WO2016044839A2 (en) Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
CN111420024A (zh) 杆菌酞a在制备预防和治疗冠状病毒的药物中的应用
WO2017004499A1 (en) Compositions and methods for the treatment of viral infection
Rios-Ibarra et al. Nanoparticle‑based antiviral strategies to combat the influenza virus
Kim et al. Influenza immunization with trehalose-stabilized virus-like particle vaccine using microneedles
JP2013515490A5 (OSRAM)
JP2019532635A5 (OSRAM)
CN101842092A (zh) 用于治疗流感感染的材料和方法
CN101340902B (zh) 用半胱胺化合物处理病毒感染的材料和方法
JP2024529291A (ja) ウイルス感染症の処置および予防のための組成物および方法
US20240075012A1 (en) Compositions and methods for treating viral infection
EA201201362A1 (ru) Фармацевтический аэрозольный состав ингибиторов протеаз и его получение
CN111971034A (zh) 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用